UK Stem Cell Bank (UKSCB)

The UK Stem Cell Bank (UKSCB) is the single national repository for UK-derived human embryonic stem cell (hESC) lines — the body a research administrator means when a licensed embryo-research establishment talks about depositing a newly-derived line, or a separate research group applies for access to one already banked. It is hosted by the National Institute for Biological Standards and Control (NIBSC), itself part of the Medicines and Healthcare products Regulatory Agency (MHRA), and has operated since 2003 (the Medical Research Council previously acted as its secretariat until March 2023, when that function moved to MHRA). It is not a private cord-blood or dental stem-cell storage company — several UK businesses market consumer cord-blood banking under a very similar generic name, and none of them have any connection to the UKSCB, the Human Fertilisation and Embryology Act, or embryo-research governance at all.

What the UK Stem Cell Bank does

The UKSCB holds and distributes over 180 human embryonic stem cell lines, making it the sole public repository of UK-derived hESC lines. It banks both research-grade lines and clinical-grade lines meeting the Human Tissue (Quality and Safety for Human Application) Regulations 2007, and it separately conducts standardisation work — developing WHO international reference materials for advanced therapies and contributing to global best-practice guidance on pluripotent stem cell banking. For a research administrator, the practical distinction that matters is: the UKSCB is where an existing UK-derived hESC line lives and is obtained from; it is not itself the body that authorises the embryo research that created the line in the first place.

Statutory basis and how it sits alongside HFEA licensing

The UKSCB’s role is a licence-condition mechanism inside the same framework covered by the Human Fertilisation and Embryology Act and enforced by the Human Fertilisation and Embryology Authority (HFEA), not a separate licensing regime. Deriving a new hESC line still requires an HFEA research licence issued against one of the Act’s closed Schedule 2 purposes, and the line remains subject to the Act’s 14-day limit on keeping or using the embryo it was derived from. Once a line exists, HFEA-licensed centres are typically required, as a condition of their licence, to deposit it with the UKSCB so it becomes available to other approved researchers rather than remaining a single lab’s private resource — the deposit-and-access step the UKSCB actually runs is downstream of, and additional to, the HFEA licensing step already documented on this site.

The UK Stem Cell Bank Steering Committee

Deposit and access decisions are not made by NIBSC staff alone. The UK Stem Cell Bank Steering Committee, established in December 2002 following a House of Lords Select Committee recommendation, is the independent national committee that reviews applications to deposit a line with the Bank or to access one already held, develops and maintains the Code of Practice the Bank operates under, monitors compliance, and reports annually. It is an active, currently-sitting body (not a historical one that has since lapsed) — as of this writing it holds three scheduled meetings a year, is chaired by an academic ethicist, and its roughly eight members span stem cell biology, bioethics, medical law, theology, and a lay member, reflecting the committee’s origin as an ethics-and-governance body rather than a purely scientific review panel. It reports to the MHRA, which has hosted the Bank’s secretariat since March 2023, and its remit is explicitly to ensure UK human embryonic stem cell line research complies with HFEA regulation — it does not duplicate or override the HFEA’s own licensing function, it applies an additional, cell-line-specific layer of ethical review on top of it.

Accessing or depositing a line

A researcher who wants to use an hESC line already held by the UKSCB applies directly to the Steering Committee, rather than to the HFEA — because no new embryo is being created, kept, or used, the HFEA’s own licensing trigger under Section 3(1) of the Act does not apply to this step. The Bank publishes guidance on the application form, shipment requirements, and storage/handling conditions attached to any approved line. A centre depositing a newly-derived line follows a parallel but separate application to the same Steering Committee, assessed against the Code of Practice’s quality and provenance requirements (consent documentation, derivation method, characterisation data) rather than against the Act’s Schedule 2 research purposes, which were already satisfied at the earlier HFEA-licensing stage.

Practical implications for research administrators

• Don’t conflate “UK Stem Cell Bank” with a commercial cord-blood or tissue-banking service when triaging a researcher’s question or an incoming enquiry — the generic-sounding name is shared with an unrelated consumer industry, but the UKSCB itself is a regulatory-adjacent, publicly-hosted research infrastructure body.
• Track UKSCB deposit/access applications as a separate compliance and timeline item from the HFEA research licence itself — they go to different bodies, are assessed against different criteria (Code of Practice provenance/consent standards vs. Schedule 2 research purposes), and a licence-condition deposit obligation can create a deadline independent of the licence’s own renewal cycle.
• If a project only needs access to an existing banked line rather than deriving a new one, the relevant approval is the Steering Committee’s access review, not a fresh HFEA research licence — confirm which situation actually applies before scoping the wrong approval pathway.
• For clinical-grade (rather than research-grade) line use, confirm the specific line meets the Human Tissue (Quality and Safety for Human Application) Regulations 2007 before assuming research-grade access terms apply.
• Route any question about a UK-derived hESC line’s provenance, characterisation data, or consent documentation to the UKSCB/NIBSC directly — the HFEA licenses the research activity that created the line, but the Bank is the actual custodian of the line’s own records once deposited.

Frequently asked questions

What is the UK Stem Cell Bank?

The single national repository, hosted by NIBSC (part of the MHRA) since 2003, that banks and distributes UK-derived human embryonic stem cell lines for research and clinical use, with deposit and access decisions reviewed by the independent UK Stem Cell Bank Steering Committee.

Is the UK Stem Cell Bank the same as a private cord-blood bank?

No. Several UK companies market consumer umbilical cord-blood or cord-tissue storage using very similar generic wording (“stem cell bank UK”). Those are unrelated private businesses regulated separately (typically under the Human Tissue Authority for storage licensing); they have no connection to the UKSCB, NIBSC, or HFEA embryo-research governance.

Do I still need an HFEA research licence if I’m only accessing an existing line from the UKSCB?

Generally no HFEA research licence is needed for that specific step, because accessing an already-derived line does not itself create, keep, or use a human embryo — the trigger for HFEA licensing under Section 3(1) of the Act. The access application instead goes to the UK Stem Cell Bank Steering Committee. A project may still need other approvals (Research Ethics Committee opinion, institutional governance) depending on what it does with the line afterward.

Is the UK Stem Cell Bank Steering Committee still active?

Yes. It has met continuously since its December 2002 establishment, holds a regular annual meeting schedule, and reports to the MHRA, which took over hosting the Bank’s secretariat from the Medical Research Council in March 2023.

What’s the difference between the UK Stem Cell Bank and the HFEA?

The HFEA licenses the embryo research that creates a human embryonic stem cell line in the first place, under the Human Fertilisation and Embryology Act’s Schedule 2 framework. The UK Stem Cell Bank is a separate, later-stage body: it banks the resulting lines and, through its Steering Committee, reviews deposit and access applications so approved lines can be shared across UK research rather than staying siloed in the lab that derived them.